PG-2

PG-2 is an investigational drug candidate being developed by Ingalfarma for the treatment of herpes labialis, commonly known as cold sores. Currently in the preclinical stage of development, PG-2 is part of Ingalfarma's specialty pharmaceutical pipeline focused on oral and mucosal health. While specific details regarding its molecular target and mechanism of action have not been publicly disclosed, the product is positioned as a potential topical or local treatment for managing outbreaks of the herpes simplex virus on the lips. It is categorized as a specialty pharma product rather than a biologic, suggesting a small molecule or non-biologic formulation.